Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.43 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534021 | 0.85 | CA12 (0.68) | CA12CA2CA7CA14ALDH1A1 | |
| SCHEMBL27870560 | 0.82 | CA2 (0.55) | CA12CA2CA7CA14ALDH1A1 | |
| SCHEMBL195152 | 0.82 | CA2 (0.55) | CA12CA2CA7CA14ALDH1A1 | |
| SCHEMBL10680125 | 0.79 | L3MBTL1 (0.55) | CA12CA2CA7CA14ALDH1A1 | |
| SCHEMBL6055917 | 0.79 | CA12 (0.52) | CA12CA2CA7CA14ALDH1A1 | |
| SCHEMBL13770963 | 0.79 | CA2 (0.53) | CA12CA2CA7CA14ALDH1A1 | |
| SCHEMBL6831298 | 0.79 | HTT (0.55) | CA12CA2CA14ALDH1A1CA1 | |
| SCHEMBL24990593 | 0.78 | CA12 (0.59) | CA12CA2CA7CA14ALDH1A1 | |
| SCHEMBL11690253 | 0.78 | CA12 (0.59) | CA12CA2CA7CA14ALDH1A1 | |
| SCHEMBL6029240 | 0.78 | CA12 (0.59) | CA12CA2CA7CA14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103224506-A | Antiviral indoles | ANGELETTI P IST RICHERCHE BIO | 2013-07-31 | — | — | CN | disclosed |
| EP-2121707-B1 | ANTIVIRAL INDOLES | ANGELETTI P IST RICHERCHE BIO (IT) | 2012-12-05 | — | — | EP | disclosed |
| US-8101595-B2 | Antiviral indoles | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA (IT) | 2012-01-24 | — | — | US | disclosed |
| US-7781422-B2 | Antiviral indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-08-24 | — | — | US | disclosed |
| US-20100076046-A1 | Antiviral Indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-03-25 | — | — | US | disclosed |
| CN-101563352-A | Antiviral indoles | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-10-21 | — | — | CN | disclosed |
| US-20080153895-A1 | Antiviral indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076046-A1 | Antiviral Indoles | IDO1, ZC3HAV1, IFNAR1 | CA12 4222/4885CA2 4792/4885CA7 4186/4885 |
| US-20080153895-A1 | Antiviral indoles | IDO1, ZC3HAV1, YBX1 | CA12 4420/4885CA2 4826/4885CA7 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.